Stockscreener 앱 받기
0.0158
75.56%
0.0068
전일 마감가:
$0.009
열려 있는:
$0.0157
하루 거래량:
1,320
Relative Volume:
0.08
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.63%
1개월 성능:
+8.22%
6개월 성능:
-37.05%
1년 성능:
+0.00%
1일 변동 폭
$0.015
$0.0158
1주일 범위
$0.009
$0.0158
52주 변동 폭
$0.005
$0.1001
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
명칭
Nls Pharmaceutics Ag
전화
41 44 512 21 50
주소
The Circle 6, Zurich
NLSPW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NLSPW | 0.0158 | 0 | 0 | 0 | 0 | 0.00 |
| VRTX | 449.80 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.15 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.49 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nls Pharmaceutics Ag 주식(NLSPW)의 최신 뉴스
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire
NLS Pharmaceutics Merges with Kadimastem for Strategic Growth - TipRanks
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria
NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Outlines Capital and Share Strategy - TipRanks
NLS Pharmaceutics announces 1-for-40 reverse share split - TipRanks
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
BREAKING: NPA to ballot pharmacists on working to rule - The Pharmacist
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Yahoo Finance
Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Primecap Management Co. CA - MarketBeat
National Beverage: Growth Fizzing Out With Questionable Earnings Quality - Seeking Alpha
London NHS trust paid out more than £1.3m in mental health claims in 5years - Time 107.5
North East London NHS trust pays out £1.3m in mental health negligence cases - Waltham Forest Echo
Keeping an Eye on Newell Brands Inc (NWL) After Insider Trading Activity - Knox Daily
GSK Velu’s Neuberg Diagnostics in talks with 360One, M&G Investments for $100 mn pre-IPO fundraise - Moneycontrol
Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Arizona State Retirement System - Defense World
RSV medication among new Pharmac funding options - RNZ
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex
How To Buy NLS Pharmaceutics AG Stock Online in August 2024 - Traders Union
NLS Pharmaceutics (NASDAQ:NLSP) Trading 4.3% Higher - Defense World
NLS Pharmaceutics Gains PwC’s Endorsement - TipRanks
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump - MSN
Nls Pharmaceutics Ag (NLSPW) 재무 분석
Nls Pharmaceutics Ag (NLSPW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):